At present, PD-L1 expression, tumor mutation burden (TMB), and tumor infiltrating lymphocytes (TILs) were reported as possible biomarkers for distinguishing responders and non-responders in NSCLC and other solid tumors [8–10]. The gene discussed is CD274; the disease is neoplasm.